SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT ID: NCT03050554

Last Updated: 2024-08-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-26
• Study Completion Date: 2019-10-07

Brief Summary

The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).

Avelumab is considered experimental because it is not approved by the United States (U.S.) Food and Drug Administration (FDA) for the treatment of cancer. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies are made to recognize, target and bind to specific proteins on the cells that make up your tissues. Avelumab is designed to block the interaction between PD-1, a known immune checkpoint, and PD-L1. By blocking this interaction, the immune system may be stimulated, allowing it to more effectively recognize and attack the cancer.

Stereotactic Body Radiation Therapy (SBRT) is a type of radiation that uses precise targeting to deliver a high dose of radiation to the tumor over a short period of time. A positioning cushion such as Vac-lok will be used during radiation treatment that is custom made. This custom mold forms to the contours of the subjects body to allow for proper positioning comfort and stability.

Detailed Description

This is a single arm open label Phase I/II study that will consist of two parts. In Phase I, investigators will assess the safety and tolerability of SBRT combined with Avelumab. In Phase II, investigators will determine whether SBRT combined with Avelumab improves relapse free survival. Subjects with Stage I NSCLC who are not undergoing surgical resection will be candidates for enrollment. Subjects will receive definitive stereotactic body radiation (SBRT) in 4-5 fractions combined with concurrent and adjuvant Avelumab at 10mg/kg for a total of 6 cycles. Subjects will be evaluated for safety as measured by the occurrence of adverse events, serious adverse events, and laboratory abnormalities. Three blood draws will be obtained to analyze anti-tumor immune responses and immune correlates.

Conditions

Early Stage Non-Small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SBRT+Avelumab

SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)

Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles

Group Type: EXPERIMENTAL

Avelumab

Intervention Type: DRUG

Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles

SBRT

Intervention Type: RADIATION

SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)

Interventions

Avelumab

Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles

Intervention Type: DRUG

SBRT

SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)

Intervention Type: RADIATION

Other Intervention Names

Bavencio; Stereotactic Body Radiation Therapy

Eligibility Criteria

Inclusion Criteria

• Tumor(s) to be treated is(are) ≤ 5.0 cm or ≤250 cm3
• Stage I NSCLC and is deemed medically inoperable or refuses surgical resection.
• Life expectancy ≥ 9 months.
• Acceptable organ and marrow function

Exclusion Criteria

• Prior organ transplantation, including allogeneic stem cell transplantation
• Significant acute or chronic infections including:

• Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
• Known history of HBV or HCV
• Active autoimmune disease

• Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
• Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
• Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable
• Current use of immunosuppressive medication, EXCEPT for the following:

• intranasal, inhaled, topical steroids, or local steroid injection (eg, intra-articular injection)
• Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent
• Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
• Cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication.
• Known severe hypersensitivity reactions to monoclonal antibodies any history of anaphylaxis, or uncontrolled asthma
• Pregnancy or lactation
• Known alcohol or drug abuse
• Prior radiotherapy to the treatment site(s).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

Andrew Sharabi

OTHER

Sponsor Role: lead

Responsible Party

Andrew Sharabi

Assistant Clinical Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Andrew Sharabi, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of California, San Diego

Locations

UC San Diego Moores Cancer Center

La Jolla, California, United States

Sanford Health

Sioux Falls, South Dakota, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

161591

Identifier Type: -

Identifier Source: org_study_id